Development of 3D Angle-Interlock Woven Preforms for Composites

The advent of three dimensional (3D) reinforcements has been mainly to overcome the issue of delamination and improve upon the damage tolerance properties by introducing fibres in the thickness direction for advanced composite applications. 3D preforms can be developed using various techniques. Angle-interlock weaving is one of them. This paper details about the efforts being put at CSIR-NAL for developing angle-interlock woven preforms. Four types of angle-interlock structures viz., layer-to-layer and through thickness (both with and without stuffer yarns) were developed using 6K, 400 Tex TC-33 grade Carbon tows on a custom designed handloom. The preforms without stuffer yarns had 4 layers of warp and were of 1.5± 0.2 mm thick. Preforms with stuffer yarns had 6 layers of warp (including 2 stuffer yarn layers) and were of 2.3±0.1 mm thick. Thermoset composites were prepared from these preforms using EPOLAM 2063 (an epoxy based resin system) by RTM process. The fibre weight fraction for these composites ranged from 0.53 to 0.58 and they were subjected to mechanical tests such as tensile, flexural and interlaminar shear strength. Test results showed improved response (in the warp direction) with respect to shear properties while the tensile and flexural properties were equivalent to that of the plain woven composites

ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity

Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade therapy is able to induce long-lasting antitumor responses in a fraction of cancer patients. Nonetheless, there is still room for improvement in the quest for new therapeutic combinations. ICOS costimulation has been underscored as a possible target to include with CTLA-4 blocking treatment. Herein, we describe an ICOS agonistic aptamer that potentiates T cell activation and induces stronger antitumor responses when locally injected at the tumor site in combination with anti-CTLA-4 antibody in different tumor models. Furthermore, ICOS agonistic aptamer was engineered as a bi-specific tumor-targeting aptamer to reach any disseminated tumor lesions after systemic injection. Treatment with the bi-specific aptamer in combination with CTLA-4 blockade showed strong antitumor immunity, even in a melanoma tumor model where CTLA-4 treatment alone did not display any significant therapeutic benefit. Thus, this work provides strong support for the development of combinatorial therapies involving anti-CTLA-4 blockade and ICOS agonist tumor-targeting agents

ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity

Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade therapy is able to induce long-lasting antitumor responses in a fraction of cancer patients. Nonetheless, there is still room for improvement in the quest for new therapeutic combinations. ICOS costimulation has been underscored as a possible target to include with CTLA-4 blocking treatment. Herein, we describe an ICOS agonistic aptamer that potentiates T cell activation and induces stronger antitumor responses when locally injected at the tumor site in combination with anti-CTLA-4 antibody in different tumor models. Furthermore, ICOS agonistic aptamer was engineered as a bi-specific tumor-targeting aptamer to reach any disseminated tumor lesions after systemic injection. Treatment with the bi-specific aptamer in combination with CTLA-4 blockade showed strong antitumor immunity, even in a melanoma tumor model where CTLA-4 treatment alone did not display any significant therapeutic benefit. Thus, this work provides strong support for the development of combinatorial therapies involving anti-CTLA-4 blockade and ICOS agonist tumor-targeting agents

Exposure media a critical factor for controlling dissolution of CuO nanoparticles

Dissolution is an important property that influences nanoparticle abundance and biological responses, and often becomes a critical factor in determining the safety of nanoparticles. In our study, the dissolution behavior of commercial (c-CuO) and synthesized CuO (s-CuO) nanoparticles, of size 31?�?4 nm and 7?�?1 nm, respectively, in a range of simulated aqueous media (artificial sea water, artificial lysosomal fluid, simulated body fluid, and 1 mM NaNO3) was assessed. The study demonstrated significant differences in the dissolution behavior of the nanoparticles based on the exposure concentration and exposure media. In biological media, both c-CuO and s-CuO demonstrated more than 80% dissolution within 12 to 24 h as compared to less than 15% dissolution in environmental media over the 7-day period. Due to the inherent size difference between c-CuO and s-CuO nanoparticles, the rate of dissolution was found to be higher in the case of s-CuO nanoparticles. To validate the role of dissolution, the microbial response of CuO nanoparticles and its ionic species was evaluated on E. coli. This study highlights the interplay between particulate and ionic form and experimentally validates how the suspension media acts as a critical factor governing the solubility of nanoparticles.by Swaroop Chakraborty , Ashwathi Nair, ManasPaliwal, Agnieszka Dybowska and Superb K.Misr